Svein Otto Fredwall

Svein Otto Fredwall

Auto-generated profile, based on publicly available information

Svein Otto Fredwall

TRS National Resource Centre for Rare Disorders, Sunnaas Rehabilitation Hospital, Nesodden, Norway

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
SFSvein O. Fredwall
Svein O. Fredwall
GMGrethe Maanum
Grethe Maanum
HJHeidi Johansen
Heidi Johansen
HSHildegun Snekkevik
Hildegun Snekkevik
RSRavi Savarirayan
Ravi Savarirayan
ILIngeborg B. Lidal
Ingeborg B. Lidal
This article provides an overview of the current knowledge on medical complications, health characteristics, and psychosocial issues in adults with achondroplasia. We have used a scoping review methodology particularly recommended for mapping and summarizing existing research evidence, and to identify knowledge gaps. The review process was conducted in accordance with the PRISMA‐ScR guidelines (Preferred Reporting Items for Systematic reviews and Meta‐Analyses Extension for Scoping Reviews). The selection of studies was based on criteria predefined in a review protocol. Twenty‐nine publications were included; 2 reviews, and 27 primary studies. Key information such as reference details, study characteristics, topics of interest, main findings and the study author's conclusion are presented in text and tables. Over the past decades, there has only been a slight increase in publications on adults with achondroplasia. The reported morbidity rates and prevalence of medical complications are often based on a few studies where the methodology and representativeness can be questioned. Studies on sleep‐related disorders and pregnancy‐related complications were lacking. Multicenter natural history studies have recently been initiated. Future studies should report in accordance to methodological reference standards, to strengthen the reliability and generalizability of the findings, and to increase the relevance for implementing in clinical practice.

25 May 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SFSvein O. Fredwall
Svein O. Fredwall
USUnni Steen
Unni Steen
OVOlga de Vries
Olga de Vries
CRCecilie F. Rustad
Cecilie F. Rustad
HEHeidi Beate Eggesbø
Heidi Beate Eggesbø
GMGrethe Månum
Grethe Månum
Background: Symptomatic spinal stenosis (SSS) is a well-known medical complication in achondroplasia. The reported prevalence of SSS is 10 to 30%, an estimate based on small studies or selected populations. No population-based studies exist currently. Furthermore, the relationship between SSS and physical functioning has not been investigated in detail. The aims of this study were to describe the prevalence of SSS in Norwegian adults with achondroplasia, and to explore the impact of SSS on physical functioning.Methods: This was a population-based study on Norwegian community-dwelling adults with genetically confirmed achondroplasia. Prevalence of SSS was defined by clinical symptoms, and confirmed by imaging or surgical reports. Physical functioning was assessed by walking capacity (6-min walk test), hand strength (Grippit), and activities of daily living (the Health Assessment Questionnaire, HAQ). Pain was assessed by pain site locations and intensity (Numeric Rating Scale, NRS).Results: In total, 50 participants were included (27 males, 23 females). Median age was 41 years (range 16 to 87 years), 34 (68%) had SSS. The estimated median age at first symptom onset was 33 years (95% confidence interval (CI) 29 to 43 years), range 10 to 67 years. The majority had multiple spinal levels affected. The walking distance was 110 m shorter in the SSS group (95% CI − 172 to − 40 m) as compared with the non-SSS group (p < 0.01). There was no considerable difference in hand strength between the two groups. Mean HAQ scores (0–3) for walking and hygiene were significantly higher in the SSS group, reflecting more activity limitations. Mean differences were 0.9 (95% CI 0.3 to 1.4,p < 0.01) and 0.6 (95% CI 0.2 to 1.0, p < 0.01). Pain intensity (NRS 0–10) was also significantly higher in the SSS group with a mean difference of 3.2 (95% CI 0.6 to 5.6,p = 0.02).Conclusions: SSS was highly prevalent in Norwegian adults with achondroplasia, with symptom onset at young age, and multiple spinal levels affected. The presence of SSS was associated with reduced walking distance, activity limitations, and more pain. The findings underline the importance of thorough assessment and monitoring of SSS in achondroplasia, including a formal assessment of physical functioning.

13 June 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
RSRavi Savarirayan
Ravi Savarirayan
WBWagner Baratela
Wagner Baratela
TBThomas Butt
Thomas Butt
VCValérie Cormier-Daire
Valérie Cormier-Daire
MIMelita Irving
Melita Irving
SFSvein O. Fredwall
Svein O. Fredwall
Background: Achondroplasia is associated with disproportionate short stature and significant and potentially severe medical complications. Vosoritide is the first medicine to treat the underlying cause of achondroplasia and data from phase 3 and phase 2 extension studies showed effects on growth and body proportions. However, there are currently no long-term data available on the direct impact on endpoints such as medical complications and health-related quality of life (HRQoL). This study explored the perceived impact of achondroplasia on medical complications, HRQoL, healthcare resource use and mortality, and potential modifying effects of vosoritide, based on published evidence and expert opinion. Structured expert opinion was obtained by an international modified Delphi study among 14 experts in managing achondroplasia performed on a virtual platform and consisting of an explorative phase followed by an anonymous individual rating round. Results: Overall, the panelists expect that in individuals starting long-term treatment between 2 years of age and puberty, growth velocity increases observed in the clinical trials will be maintained until final height is reached (92% agreement) and will likely result in clinically meaningful improvements in upper-to-lower body segment ratio (85%). Earlier treatment initiation will likely result in a greater final height (100%) and more likely improve proportionality (92%) than later treatment. Although current data are limited, ≥ 75% of panelists find it conceivable that the earlier long-term treatment is started, the greater the probability of a positive effect on the lifetime incidence of symptomatic spinal stenosis, kyphosis, obstructive sleep apnea, and foramen magnum stenosis. These are among the most clinically important complications of achondroplasia because of their high impact on comorbidity, mortality, and/or HRQoL. A positive effect of vosoritide on the incidence of surgeries through lifetime was considered more likely with earlier long-term treatment (90%). Conclusions: This explorative study, based on international expert opinion, provides further insight into the medical and functional impacts of achondroplasia and how these might be modified through long-term use of vosoritide. The results can be used to guide the direction and design of future research to validate the assumptions and to discuss potential treatment outcomes with disease modifying therapies with families and clinicians.

31 December 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
OVOlga Marieke de Vries
Olga Marieke de Vries
HJHeidi Johansen
Heidi Johansen
SFSvein Otto Fredwall
Svein Otto Fredwall
This cross‐sectional Physical Fitness Study compared cardiorespiratory fitness (VO2 peak), six‐minute walk test (6MWT), muscle strength (30sSTS), balance (BESS), and self‐reported physical activity level (IPAQ) in Norwegian adults with achondroplasia (ACH) to reference values of average‐statured individuals. The feasibility of the physical fitness tests and IPAQ was explored. Forty‐three adults (22 women) participated. Mean age was 38 years (range 16–69 years). Mean differences (95% CI) for men and women with ACH compared to reference values were: VO2 peak. −7.0 m/min/kg (−13.6 to −0.5, p = .037), and − 7.9 ml/kg/min (−11.6 to −4.3, p < .001); 6MWT −270.8 m (−340.4 to −201.2, p < .001), and − 196.7 m (−244.3 to −149.0, p = .001); 30sSTS ‐4.6 repetitions (−7.8 to −1.5, p = .006), and − 1.1 repetitions (−3.4 to 1.1, p = .335). There were no differences within ACH participants, except for VO2 peak, where men performed better. Sufficient physical activity (> 600 metabolic equivalent of task weekly) was achieved by 79% of the participants. The feasibility of the 6MWT and 30sSTS was good. There was a strong correlation between the VO2 peak and 6MWT (men: r = 0.63, p = .007; women: r = 0.71, p < .001). The findings indicate that the 6MWT and 30sSTS test are useful in assessing functional exercise capacity and muscle strength in adults with ACH.

18 November 2020 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SFSvein O. Fredwall
Svein O. Fredwall
JLJennifer Linge
Jennifer Linge
OLOlof Dahlqvist Leinhard
Olof Dahlqvist Leinhard
LKLisa Kjønigsen
Lisa Kjønigsen
HEHeidi Beate Eggesbø
Heidi Beate Eggesbø
STSerena Tonstad
Serena Tonstad
Purpose An increased cardiovascular mortality has been reported in achondroplasia. This population-based, case–control study investigated cardiovascular risk factors and body composition in Norwegian adults with achondroplasia. Methods We conducted anthropometric, clinical, and laboratory assessments in 49 participants with achondroplasia, of whom 40 completed magnetic resonance imaging (MRI) for body composition analysis. Controls consisted of 98 UK Biobank participants, matched for body mass index (BMI), sex, and age. Results Participants were well matched for BMI (33.3 versus 32.5 kg/m2) and sex, but achondroplasia participants were younger than controls (mean age 41.1 versus 54.3 years). Individuals with achondroplasia had lower age-adjusted mean blood pressure, total and low-density lipoprotein (LDL) cholesterol, and triglycerides compared with controls, but similar fasting glucose and HbA1c values. Age-adjusted mean visceral fat store was 1.9 versus 5.3 L (difference −2.7, 95% confidence interval [CI] −3.6 to −1.9; P < 0.001), abdominal subcutaneous fat was 6.0 versus 11.2 L (−4.7, 95% CI −5.9 to −3.4; P < 0.001), and liver fat was 2.2 versus 6.9% (−2.8, 95% CI −5.2 to −0.4; P = 0.02). Conclusion Despite a high BMI, the cardiovascular risks appeared similar or lower in achondroplasia compared with controls, indicating that other factors might contribute to the increased mortality observed in this condition.

7 April 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SFSvein O. Fredwall
Svein O. Fredwall
BØBritt Øverland
Britt Øverland
HBHanne Berdal
Hanne Berdal
SBSøren Berg
Søren Berg
HWHarald Weedon-Fekjær
Harald Weedon-Fekjær
GMGrethe Månum
Grethe Månum
Background: Previous studies have found a high prevalence of obstructive sleep apnea (OSA) in children with achondroplasia, but clinical studies on this complication in adults with achondroplasia are lacking. Objectives: This population-based, cross-sectional study investigated the prevalence, severity, and predictive factors of OSA in Norwegian adults with achondroplasia. Methods: We collected clinical data on 49 participants. Participants without a preexisting diagnosis of OSA had an overnight sleep registration. OSA was defined as an apnea–hypopnea index (AHI) ≥ 5 plus characteristic clinical symptoms, or AHI ≥ 15. We used the Berlin Questionnaire to assess clinical symptoms of OSA. Results: OSA was found in 59% (29/49) of the participants (95% confidence interval 44 to 73%), of whom 59% (17/29) had moderate to severe OSA (AHI ≥ 15), and 48% (14/29) were previously undiagnosed. Variables predictive of OSA were: excessive daytime sleepiness; unrested sleep; loud snoring; observed nocturnal breathing stops; hypertension; age > 40 years; and BMI > 30 kg/m2. Conclusion: OSA was highly prevalent in Norwegian adults with achondroplasia, which we believe is representative of this population worldwide. Follow-up of adults with achondroplasia should include assessment of symptoms and signs of OSA, with a low threshold for conducting an overnight sleep registration if findings suggestive of OSA are present.